Physician profile
Nicholas Harper
NPI 1396124624
$2,619.51
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $425 · 2021: $330 · 2022: $275 · 2023: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $679.35 | 2019-2023 | |
| Abbvie INC. | $483.39 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $480.27 | 2019-2022 | |
| Glaxosmithkline, LLC. | $321.72 | 2019-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $273.99 | 2019-2020 | |
| Amgen INC. | $67.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.78 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $45.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.90 | 2019 | |
| Endo Pharmaceuticals INC. | $35.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.54 | 2022 | |
| Allergan, INC. | $31.61 | 2019-2020 | |
| Astellas Pharma US INC | $31.51 | 2019 | |
| Mylan Specialty L.P. | $24.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.72 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.